Cost effectiveness of the German screen-and-treat strategy for postmenopausal osteoporosis

PharmacoEconomics

Volumn 26, Issue 6, 2008, Pages 513-536

  Mueller, Dirk ^a   Weyler, Eva ^a   Gandjour, Afschin ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Alendronic acid, therapeutic use; Bone mineral density; Cost utility; Osteoporosis, treatment; Risedronic acid, therapeutic use; Screening; Teriparatide, therapeutic use

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; PARATHYROID HORMONE[1-34]; RISEDRONIC ACID;

ADULT; AGED; ARTICLE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FRAGILITY FRACTURE; GERMANY; HEALTH CARE COST; HEALTH PROGRAM; HUMAN; MONTE CARLO METHOD; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SCREENING TEST; SECONDARY PREVENTION;

EID: 43949091498     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200826060-00005     Document Type: Article

References (95)